Abstract
During the recent years considerable advances in the clinical and laboratory diagnosis of alloimmune thrombocytopenia have been done. Feto‐maternal alloimmunization is the commonest cause of cause of severe isolated fetal and neonatal thrombocytopenia. The condition results from maternal immunization against specific fetal platelet antigens (HPA). HPA‐1a is mostly implicated in Caucasians. The diagnosis is usually made at birth when an otherwise “well” term infant exhibits bleeding at delivery or few hours afterwards. The most feared complication of this disorder is the occurrence of intracranial hemorrhage (ICH) as a result of severe thrombocytopenia leading to death or neurological sequels. The diagnosis of alloimmune thrombocytopenia enables appropriate management of the index case and future pregnancies. Due to the recurrence and increasing severity of this condition in subsequent pregnancies with incompatible fetuses, antenatal management has been proposed. Predictive maternal parameters for severe fetal thrombocytopenia and therapy effectiveness are important for the development of non‐ invasive strategy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.